A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
about
Low dose cytarabine monotherapy for myelodysplastic syndromesTherapy of acute myeloid leukemia.Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.Challenges in treating older patients with acute myeloid leukemia.Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.Therapy related leukemias: susceptibility, prevention and treatment.Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndromeSurvival for older patients with acute myeloid leukemia: a population-based studyDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Differentiation of leukemia cells by chemotherapeutic agents.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Poor prognosis acute myelogenous leukemia.Modulation of cytotoxicity and differentiation-inducing potential of arabinofuranosylcytosine in myeloid leukemia cells by hematopoietic cytokines.Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes.Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution ExperienceThe nature and evolving treatment of myelodysplastic syndromes.Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
P2860
Q24234789-55FB21ED-8754-4F79-A239-5DD9A7BB612CQ31929964-D2711841-2FFA-4764-AC95-7FAC99BAEFB9Q33389465-7171DEF8-D2F1-477C-A32F-6C6BAFAF8AF7Q33706393-81CB4AB4-E38C-48B0-93EB-D0F686E0D3DFQ33985549-406E0C4E-5869-49FB-9DB0-586FF7EBA05BQ34088756-72E1C4CF-035E-404D-8355-342318BDF1E7Q34265193-AF30CD4A-17B3-4830-BF8E-551088B85225Q35937752-891D5240-D3B3-4BCA-B2D3-D9E1E8DC8AD4Q36662052-15513FD2-B473-439A-A9D2-86C3459BB6E5Q37263146-7DF3057A-21EE-4AFF-A31B-872867CCC39CQ38091393-7BE89CAD-9095-4BA1-8159-FF224C815379Q39564542-83097245-C9EB-4D60-A2FB-4DE7BE2FA575Q40420210-2BBD5DE6-8D82-4988-AD29-B36E9A102C59Q40711700-878B80D1-5A71-4235-BBC2-A693C43496E5Q40891327-131E3F6F-1D78-46F7-B269-7D53A563D7D0Q41162060-1C8D9689-6342-4D25-A4E2-22B218A1D254Q41476734-446F0502-4604-426F-9C16-D6F1FD779963Q42580669-A7278FD7-1ACA-4148-884F-9E49121E2B87Q54125443-871E90DD-2D31-4584-9DF7-37C6A2CD8BCC
P2860
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@en
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@nl
type
label
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@en
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@nl
prefLabel
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@en
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@nl
P2093
P1476
A critical appraisal of low-do ...... and myelodysplastic syndromes.
@en
P2093
B D Cheson
D M Jasperse
M A Friedman
P304
P356
10.1200/JCO.1986.4.12.1857
P407
P577
1986-12-01T00:00:00Z